Notable Labs CEO Thomas Bock resigns; CSO Wagner named interim CEO

Notable Labs, Ltd.

Thomas Bock resigned as CEO and director effective Aug 26, 2024; no disagreement with company.
Joseph Wagner, CSO since 2020, appointed interim CEO; board initiates search for permanent CEO.
Bock retained as consultant for 3 years: $21,875/month year 1, $10,937/month years 2-3; option extension to 10th anniversary.
Wagner's annual base salary increased to $408k as of April 1, 2024; target bonus 30% of base.
Company reaffirms plan to initiate volasertib Phase 2 program in coming months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas A. Bock

Chief Executive Officer

Notable Labs, Ltd.

Effective: 2024-08-26
Successor: Joseph Wagner
Filed: August 26, 2024, 7:59 PM ET

On August 26, 2024, Dr. Thomas A. Bock resigned from his positions as Director and as Chief Executive Officer of Notable Labs, Ltd.

Appointed (interim)

Joseph Wagner

Chief Executive Officer

Notable Labs, Ltd.

Effective: 2024-08-26
Filed: August 26, 2024, 7:59 PM ET

Simultaneously, on such date, Dr. Joseph Wagner, the Company’s Chief Scientific Officer, was also appointed as Chief Executive Officer on an interim basis while the Board of Directors completes a search for a new Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas A. Bock resigned as Chief Executive Officer at Notable Labs, Ltd..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On August 26, 2024, Dr. Thomas A. Bock resigned from his positions as Director and as Chief Executive Officer of Notable Labs, Ltd.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.98

Joseph Wagner was appointed as Chief Executive Officer at Notable Labs, Ltd..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Simultaneously, on such date, Dr. Joseph Wagner, the Company’s Chief Scientific Officer, was also appointed as Chief Executive Officer on an interim basis while the Board of Directors completes a search for a new Chief Executive Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-033892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.